FeesSafety
Pluang+

FDA approves CardioGuide HF App, letting heart failure patients track lung artery pressure on smartphones.

Market News
05 Oct 2026, 16:00 WIB
PRNewsWire
View Source
Bullish
FDA approves CardioGuide HF App, letting heart failure patients track lung artery pressure on smartphones.

Abbott received FDA approval for updates to its CardioMEMS HF System, enabling U.S. heart failure patients to view pulmonary artery pressure (PAP) readings on the new CardioGuide HF App. This app helps patients monitor their condition and receive personalized medication updates, allowing earlier intervention before symptoms worsen. The system, proven to reduce hospitalizations and mortality, now includes a Dynamic Treatment Plan feature that sends medication adjustments directly to patients. Abbott plans to launch these features later this year, enhancing patient engagement and care management between doctor visits.

Abbott Laboratories (ABT) shares are trading at USD 97.53 on Pluang as of Oct 05, 2026 20:12 WIB, showing a marginal 0.03% increase for the day. This price remains closer to its 52-week low of USD 82.57 than its 52-week high of USD 134.59, indicating room for growth relative to its yearly range. The stock's dividend yield stands at 2.58%, reflecting steady income potential alongside its market cap of $168.71 billion.

More News (ABT)

Three healthcare stocks, including Abbott, raised dividends in 2026, showing strong income growth potential.

Three healthcare stocks, including Abbott, raised dividends in 2026, showing strong income growth potential.

Abbott Laboratories, Medtronic, and Cigna Group each raised their dividends in 2026, highlighting the healthcare sector's resilience and steady income potential. Abbott marked its 54th consecutive year of dividend increases despite tighter earnings c...

Company Fundamentals
Bullish
8 hours ago
Abbott shares drop over 17% in 2026, with 5-year investment losing value amid growth challenges.

Abbott shares drop over 17% in 2026, with 5-year investment losing value amid growth challenges.

Abbott Laboratories' stock fell 17.79% in 2026, declining from $125.29 to $103.00, underperforming the S&P 500's 1.16% gain. Despite a $21 billion acquisition of Exact Sciences and plans to spin off its nutrition business, Abbott's growth slowed due ...

Market News
Bearish
1 day ago
Continuous Ketone Monitoring market to hit $5.48B by 2036, driven by tech advances and diabetes care integration

Continuous Ketone Monitoring market to hit $5.48B by 2036, driven by tech advances and diabetes care integration

The global Continuous Ketone Monitoring (CKM) market is projected to grow from $118 million in 2026 to $5.48 billion by 2036, at a CAGR of 46.8%. Growth is fueled by rising diabetic ketoacidosis cases, adoption of continuous glucose monitoring, and u...

Market News
Bullish
2 days ago
Dividend Kings Abbott, McDonald's, and Tennant offer buying opportunities amid recent pullbacks and strategic moves.

Dividend Kings Abbott, McDonald's, and Tennant offer buying opportunities amid recent pullbacks and strategic moves.

Abbott Laboratories, McDonald's, and Tennant, all Dividend Kings with over 50 years of consecutive dividend increases, have recently seen their stock prices dip, presenting buying opportunities. Abbott plans to spin off its struggling nutrition divis...

Company Fundamentals
Bullish
2 days ago
Dividend Kings Abbott, McDonald's, and Tennant offer buying opportunities amid recent pullbacks and strategic moves.

Dividend Kings Abbott, McDonald's, and Tennant offer buying opportunities amid recent pullbacks and strategic moves.

Abbott Laboratories, McDonald's, and Tennant, all Dividend Kings with over 50 years of consecutive dividend growth, have recently seen their stock prices dip, creating buying opportunities. Abbott plans to spin off its struggling nutrition division t...

Company Fundamentals
Bullish
3 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App